Patents by Inventor Kamlesh Jagdis Bala
Kamlesh Jagdis Bala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11911371Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.Type: GrantFiled: April 2, 2021Date of Patent: February 27, 2024Assignee: NOVARTIS AGInventors: Urs Baettig, Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark Le Grand, Katrin Spiegel
-
Publication number: 20230301970Abstract: The present invention provides a compound of formula (1) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: May 16, 2023Publication date: September 28, 2023Inventors: Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef TROXLER-SCHWAB, Joe WRIGGLESWORTH
-
Patent number: 11672782Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: November 4, 2020Date of Patent: June 13, 2023Assignee: NOVARTIS AGInventors: Kamlesh Jagdis Bala, Andrew Brearley, James Dale, Anne-Marie Edwards, Mahbub Ahmed, David Porter, Robert Alexander Pulz, Lisa Ann Rooney, David Andrew Sandham, Duncan Shaw, Nichola Smith, Jessica Louise Taylor, Roger John Taylor, Thomas Josef Troxler, Joe Wrigglesworth
-
Publication number: 20210228554Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: April 2, 2021Publication date: July 29, 2021Inventors: Urs BAETTIG, Kamlesh Jagdis BALA, Emma BUDD, Lee EDWARDS, Catherine HOWSHAM, Glyn Alan HUGHES, Darren Mark LE GRAND, Katrin SPIEGEL
-
Publication number: 20210052554Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: November 4, 2020Publication date: February 25, 2021Inventors: Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef Troxler, Joe WRIGGLESWORTH
-
Publication number: 20200268718Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: May 14, 2020Publication date: August 27, 2020Inventors: Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef TROXLER, Joe WRIGGLESWORTH
-
Publication number: 20190381011Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: December 21, 2018Publication date: December 19, 2019Inventors: Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef Troxler, Joe WRIGGLESWORTH
-
Publication number: 20190262324Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: September 26, 2018Publication date: August 29, 2019Inventors: Urs BAETTIG, Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark LE GRAND, Katrin Spiegel
-
Patent number: 10195181Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: June 16, 2016Date of Patent: February 5, 2019Assignee: Novartis AGInventors: Kamlesh Jagdis Bala, Andrew Brearley, James Dale, Anne-Marie Edwards, Mahbub Ahmed, David Porter, Robert Alexander Pulz, Lisa Ann Rooney, David Andrew Sandham, Duncan Shaw, Nichola Smith, Jessica Louise Taylor, Roger John Taylor, Thomas Josef Troxler, Joe Wrigglesworth
-
Publication number: 20170014388Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: June 16, 2016Publication date: January 19, 2017Applicant: NOVARTIS AGInventors: Kamlesh Jagdis BALA, Andrew BREARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nichola SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef Troxler, Joe WRIGGLESWORTH
-
Patent number: 9403810Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: GrantFiled: May 13, 2015Date of Patent: August 2, 2016Assignee: Novartis AGInventors: Kamlesh Jagdis Bala, Andrew Brearley, James Dale, Anne-Marie Edwards, Mahbub Ahmed, David Porter, Robert Alexander Pulz, Lisa Ann Rooney, David Andrew Sandham, Duncan Shaw, Nichola Smith, Jessica Louise Taylor, Roger John Taylor, Thomas Josef Troxler, Joe Wrigglesworth
-
Publication number: 20150329529Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.Type: ApplicationFiled: May 13, 2015Publication date: November 19, 2015Applicant: NOVARTIS AGInventors: Kamlesh Jagdis BALA, Andrew BEARLEY, James DALE, Anne-Marie EDWARDS, Mahbub AHMED, David PORTER, Robert Alexander PULZ, Lisa Ann ROONEY, David Andrew SANDHAM, Duncan SHAW, Nicole SMITH, Jessica Louise TAYLOR, Roger John TAYLOR, Thomas Josef Troxler, Joe WRIGGLESWORTH
-
Patent number: 9169251Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.Type: GrantFiled: June 26, 2014Date of Patent: October 27, 2015Assignee: Novartis AGInventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
-
Patent number: 9056867Abstract: A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: GrantFiled: September 14, 2012Date of Patent: June 16, 2015Assignee: NOVARTIS AGInventors: Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Darren Mark LeGrand, Roger John Taylor
-
Patent number: 9034879Abstract: The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.Type: GrantFiled: September 14, 2012Date of Patent: May 19, 2015Assignee: Novartis AGInventors: Kamlesh Jagdis Bala, Rebecca Butler, Stephen Paul Collingwood, Edward Charles Hall, Lee Edwards, Darren Mark Legrand, Katrin Spiegel
-
Publication number: 20140323485Abstract: A compound of Formula I and pharmaceutically acceptable salts and solvates thereof, wherein R1, R2, R3, Ra, A, B, D and E are all as defined herein. The compounds modulate the activity of CFTR and are useful in the treatment of inflammatory or obstructive airways diseases or mucosal hydration, including, for example cystic fibrosis. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.Type: ApplicationFiled: September 14, 2012Publication date: October 30, 2014Applicant: NOVARTIS AGInventors: Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Darren Mark LeGrand, Roger John Taylor
-
Publication number: 20140309254Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.Type: ApplicationFiled: June 26, 2014Publication date: October 16, 2014Inventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
-
Publication number: 20140228376Abstract: The present invention provides pyridin-oxadiazole/thiadiazole derivatives of Formula I wherein A is N or CR 4a; and (ii) or (iii) which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.Type: ApplicationFiled: September 14, 2012Publication date: August 14, 2014Applicant: NOVARTIS AGInventors: Kamlesh Jagdis Bala, Rebecca Butler, Stephen Paul Collingwood, Edward Charles Hall, Lee Edwards, Darren Mark Legrand, Katrin Spiegel
-
Patent number: 8791256Abstract: There are provided according to the invention compounds of formula (I) in free or salt form, wherein R1, R2, R3, R4, R5, R6, Q, W, X, m, n and p are as described in the specification, process for preparing them, and their use as pharmaceuticals.Type: GrantFiled: June 5, 2013Date of Patent: July 29, 2014Assignee: Novartis AGInventors: Kamlesh Jagdis Bala, Catherine Leblanc, David Andrew Sandham, Katharine Louise Turner, Simon James Watson, Lyndon Nigel Brown, Brian Cox
-
Patent number: RE46757Abstract: The present invention provides pyridine and pyrazine derivatives which restore or enhance the function of mutant and/or wild type CFTR to treat cystic fibrosis, primary ciliary dyskinesia, chronic bronchitis, chronic obstructive pulmonary disease, asthma, respiratory tract infections, lung carcinoma, xerostomia and keratoconjunctivitis sire, or constipation (IBS, IBD, opioid induced). Pharmaceutical compositions comprising such derivatives are also encompassed.Type: GrantFiled: June 30, 2015Date of Patent: March 20, 2018Assignee: Novartis AGInventors: Urs Baettig, Kamlesh Jagdis Bala, Emma Budd, Lee Edwards, Catherine Howsham, Glyn Alan Hughes, Darren Mark Legrand, Katrin Spiegel